Solicitation of Nominations for Membership To Serve on the Advisory Council on Blood Stem Cell Transplantation, 28632-28633 [2021-11213]
Download as PDF
<![CDATA[
jbell on DSKJLSW7X2PROD with NOTICES
28632
Federal Register / Vol. 86, No. 101 / Thursday, May 27, 2021 / Notices
economics, and statistics, as well as
representatives of transplant candidates,
transplant recipients, living organ
donors, and family members of
deceased and living organ donors.
Interested applicants may self-nominate
or be nominated by another individual
or organization.
Individuals selected for appointment
to the Committee will be invited to
serve for a term up to 4 years. Members
appointed as SGEs receive a stipend and
reimbursement for per diem and travel
expenses incurred for attending ACOT
meetings and/or conducting other
business on behalf of the ACOT, as
authorized by 5 U.S.C. 5703 of FACA for
persons employed intermittently in
government service.
The following information must be
included in the package of materials
submitted for each individual being
nominated for consideration: (1) A letter
of nomination stating the name,
affiliation, and contact information for
the nominee, the basis for the
nomination (i.e., what specific
attributes, perspectives, and/or skills
does the individual possess that would
benefit the workings of ACOT), and the
nominee’s field(s) of expertise; (2) a
biographical sketch of the nominee; (3)
the name, address, daytime telephone
number, and email address at which the
nominator can be contacted; and (4) a
current copy of the nominee’s
curriculum vitae. Nomination packages
may be submitted directly by the
individual being nominated or by the
person/organization recommending the
candidate.
HHS endeavors to ensure that the
membership of ACOT is fairly balanced
in terms of points of view represented
and that individuals from a broad
representation of geographic areas,
gender, and ethnic and minority groups,
as well as individuals with disabilities,
are considered for membership.
Appointments shall be made without
discrimination on the basis of age,
ethnicity, gender, sexual orientation, or
cultural, religious, or socioeconomic
status.
Individuals who are selected to be
considered for appointment will be
required to provide detailed information
regarding their financial holdings,
consultancies, and research grants or
contracts. Disclosure of this information
is required for HRSA ethics officials to
determine whether there is a conflict
between the SGE’s public duties as a
member of ACOT and their private
interests, including an appearance of a
loss of impartiality as defined by federal
laws and regulations, and to identify
VerDate Sep<11>2014
17:29 May 26, 2021
Jkt 253001
any required remedial action needed to
address the potential conflict.
Maria G. Button,
Director, Executive Secretariat.
[FR Doc. 2021–11209 Filed 5–26–21; 8:45 am]
BILLING CODE 4165–15–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Health Resources and Services
Administration
Solicitation of Nominations for
Membership To Serve on the Advisory
Council on Blood Stem Cell
Transplantation
Health Resources and Services
Administration (HRSA), Department of
Health and Human Services (HHS).
ACTION: Request for nominations.
AGENCY:
HRSA is seeking nominations
of qualified candidates to be considered
for appointment as members of the
Advisory Council on Blood Stem Cell
Transplantation (ACBSCT or Council).
ACBSCT shall advise the Secretary of
HHS (Secretary), through the HRSA
Administrator, on the activities of the
C.W. Bill Young Cell Transplantation
Program and the National Cord Blood
Inventory Program (Program).
SUMMARY:
Authority: The Council was established to
implement a statutory requirement of the
Stem Cell Therapeutic and Research Act of
2005 (Pub. L. 109–129). The Council is
governed by the Federal Advisory Committee
Act (FACA), as amended (5 U.S.C. Appendix
2), which sets forth standards for the
formation and use of advisory committees.
Written nominations for
membership on ACBSCT will be
received continuously.
ADDRESSES: Nomination packages must
be submitted to the Executive Secretary,
ACBSCT, Healthcare Systems Bureau,
HRSA, Room 08W60, 5600 Fishers
Lane, Rockville, Maryland 20857, or
sent via email to: ACBSCTHRSA@
hrsa.gov.
DATES:
FOR FURTHER INFORMATION CONTACT:
Shelley Grant, Executive Secretary,
ACBSCT, at (301) 443–8036 or email
sgrant@hrsa.gov. A copy of the ACBSCT
charter and a list of current members
may be obtained by accessing the
ACBSCT website at https://
bloodcell.transplant.hrsa.gov/about/
advisory_council/.
SUPPLEMENTARY INFORMATION: ACBSCT
was established pursuant to Public Law
109–129 as amended by Public Law
111–264; 42 U.S.C. 274k; Section 379 of
the Public Health Service Act. In
accordance with Public Law 92–463, the
PO 00000
Frm 00108
Fmt 4703
Sfmt 4703
ACBSCT was chartered on December 19,
2006. ACBSCT meets up to three times
during the fiscal year.
ACBSCT shall, as requested by the
Secretary, discuss and make
recommendations regarding the
Program. It shall provide a consolidated,
comprehensive source of expert,
unbiased analysis and recommendations
to the Secretary on the latest advances
in the science of blood stem cell
transplantation. ACBSCT shall advise,
assist, consult, and make
recommendations, at the request of the
Secretary, on (1) broad Program policy
in areas such as the necessary size and
composition of the adult donor pool
available through the Program and the
composition of the National Cord Blood
Inventory, (2) requirements regarding
informed consent for cord blood
donation, (3) accreditation requirements
for cord blood banks, (4) the scientific
factors that define a cord blood unit as
high quality, (5) public and professional
education to encourage the ethical
recruitment of genetically diverse
donors and ethical donation practices,
(6) criteria for selecting the appropriate
blood stem source for transplantation,
(7) program priorities; (8) research
priorities, and (9) the scope and design
of the Stem Cell Therapeutic Outcomes
Database.
At the request of the Secretary,
ACBSCT shall also review and advise
on issues relating more broadly to the
field of blood stem cell transplantation,
such as regulatory policy pertaining to
the compatibility of international
regulations, and actions that may be
taken by state and federal governments
and public and private insurers to
increase donation and access to
transplantation. ACBSCT shall also
make recommendations regarding
research on emerging therapies using
cells from bone marrow and cord blood.
The Council may meet up to three times
during the fiscal year.
Nominations: HRSA is requesting
nominations for voting members to
serve as Special Government Employees
(SGEs) on ACBSCT. The Council shall
consist of up to 25 members who are
SGEs and 6 ex-officio, non-voting
members. The Secretary appoints
ACBSCT SGEs with the expertise
needed to fulfill the duties of the
Council. HRSA is seeking nominees
who are outstanding authorities and
representatives of marrow donor centers
and marrow transplant centers;
representatives of cord blood banks and
participating birthing hospitals;
recipients of bone marrow transplants;
recipients of cord blood transplants;
persons who require such transplants;
family members of such a recipient or
E:\FR\FM\27MYN1.SGM
27MYN1
jbell on DSKJLSW7X2PROD with NOTICES
Federal Register / Vol. 86, No. 101 / Thursday, May 27, 2021 / Notices
family members of a patient who has
requested the assistance of the Program
in searching for an unrelated donor of
bone marrow or cord blood; persons
with expertise in bone marrow and cord
blood transplantation; persons with
expertise in typing, matching, and
transplant outcome data analysis;
persons with expertise in the social
sciences; basic scientists with expertise
in the biology of adult stem cells;
ethicists, hematology, and transfusion
medicine researchers with expertise in
adult blood stem cells; persons with
expertise in cord blood processing; and
members of the general public to serve
as members. Interested applicants may
self-nominate or be nominated by
another individual or organization.
Individuals selected for appointment
to ACBSCT will be invited to serve for
a term of 2 years, and are eligible to
serve as many as 3 consecutive 2-year
terms. Members appointed as SGEs
receive a stipend and reimbursement for
per diem and travel expenses incurred
for attending ACBSCT meetings and/or
conducting other business on behalf of
ACBSCT, as authorized by 5 U.S.C. 5703
of the FACA for persons employed
intermittently in government service.
The following information must be
included in the package of materials
submitted for each individual being
nominated for consideration: (1) A letter
of nomination stating the name,
affiliation, and contact information for
the nominee, the basis for the
nomination (i.e., what specific
attributes, perspectives, and/or skills
does the individual possess that would
benefit the workings of ACBSCT), and
the nominee’s field(s) of expertise; (2) a
biographical sketch of the nominee; (3)
the name, address, daytime telephone
number, and email address at which the
nominator can be contacted; and (4) a
current copy of the nominee’s
curriculum vitae. Nomination packages
may be submitted directly by the
individual being nominated or by the
person/organization recommending the
candidate.
HHS endeavors to ensure that the
membership of ACBSCT is fairly
balanced in terms of points of view
represented and that individuals from a
broad representation of geographic
areas, gender, and ethnic and minority
groups, as well as individuals with
disabilities, are considered for
membership. Appointments shall be
made without discrimination on the
basis of age, ethnicity, gender, sexual
orientation, or cultural, religious, or
socioeconomic status.
Individuals selected to be considered
for appointment will be required to
provide detailed information regarding
VerDate Sep<11>2014
17:29 May 26, 2021
Jkt 253001
their financial holdings, consultancies,
and research grants or contracts.
Disclosure of this information is
required for HRSA ethics officials to
determine whether there is a conflict
between the SGE’s public duties as a
member of ACBSCT and their private
interests, including an appearance of a
loss of impartiality as defined by federal
laws and regulations, and to identify
any required remedial action needed to
address the potential conflict.
Maria G. Button,
Director, Executive Secretariat.
[FR Doc. 2021–11213 Filed 5–26–21; 8:45 am]
BILLING CODE 4165–15–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of Allergy and
Infectious Diseases; Notice of Closed
Meetings
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
Allergy and Infectious Diseases Special
Emphasis Panel; NIAID Investigator Initiated
Program Project Applications (P01 Clinical
Trial Not Allowed).
Date: June 23, 2021.
Time: 10:00 a.m. to 3:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institute of Allergy and
Infectious Diseases, National Institutes of
Health, 5601 Fishers Lane, Room 3E71A,
Rockville, MD 20892 (Virtual Meeting).
Contact Person: Patricia A. Gonzales
Hurtado, Ph.D., Scientific Review Officer,
Scientific Review Program, Division of
Extramural Activities, National Institute of
Allergy and Infectious Diseases, National
Institutes of Health, 5601 Fishers Lane, Room
3E71A, Rockville, MD 20852, 240–627–3556,
Patricia.Gonzales@nih.gov.
Name of Committee: National Institute of
Allergy and Infectious Diseases Special
Emphasis Panel; NIAID Investigator Initiated
Program Project Applications (P01 Clinical
Trial Not Allowed).
Date: June 28, 2021.
PO 00000
Frm 00109
Fmt 4703
Sfmt 4703
28633
Time: 9:30 a.m. to 4:30 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institute of Allergy and
Infectious Diseases, National Institutes of
Health, 5601 Fishers Lane, Room 3E71A,
Rockville, MD 20892 (Virtual Meeting).
Contact Person: Patricia A. Gonzales
Hurtado, Ph.D., Scientific Review Officer,
Scientific Review Program, Division of
Extramural Activities, National Institute of
Allergy and Infectious Diseases, National
Institutes of Health, 5601 Fishers Lane, Room
3E71A, Rockville, MD 20852, 240–627–3556,
Patricia.Gonzales@nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.855, Allergy, Immunology,
and Transplantation Research; 93.856,
Microbiology and Infectious Diseases
Research, National Institutes of Health, HHS)
Dated: May 21, 2021.
Tyeshia M. Roberson,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2021–11208 Filed 5–26–21; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Agency Emergency Information
Collection Clearance Request for
Public Comment
AGENCY:
National Institutes of Health,
HHS.
ACTION:
Notice.
In compliance with the
requirement of the Paperwork
Reduction Act of 1995 to provide
opportunity for public comment on
proposed data collection projects, the
National Institutes of Health (NIH) will
publish periodic summaries of propose
projects to be submitted to the Office of
Management and Budget (OMB) for
review and approval.
DATES: Comments on the information
collection request must be received on
or before 10 days of this published
notice.
ADDRESSES: When commenting, please
reference the document identifier or
OMB control number. To be assured
consideration, comments and
recommendations must be submitted
within 10 days. You may send your
comments electronically to https://
www.regulations.gov. Follow the
instructions for ‘‘Comment or
Submission’’ or ‘‘More Search Options’’
to find the information collection
document(s) that are accepting
comments.
FOR FURTHER INFORMATION CONTACT: To
obtain a copy of the data collection
SUMMARY:
E:\FR\FM\27MYN1.SGM
27MYN1
]]>Agencies
[Federal Register Volume 86, Number 101 (Thursday, May 27, 2021)]
[Notices]
[Pages 28632-28633]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2021-11213]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Health Resources and Services Administration
Solicitation of Nominations for Membership To Serve on the
Advisory Council on Blood Stem Cell Transplantation
AGENCY: Health Resources and Services Administration (HRSA), Department
of Health and Human Services (HHS).
ACTION: Request for nominations.
-----------------------------------------------------------------------
SUMMARY: HRSA is seeking nominations of qualified candidates to be
considered for appointment as members of the Advisory Council on Blood
Stem Cell Transplantation (ACBSCT or Council). ACBSCT shall advise the
Secretary of HHS (Secretary), through the HRSA Administrator, on the
activities of the C.W. Bill Young Cell Transplantation Program and the
National Cord Blood Inventory Program (Program).
Authority: The Council was established to implement a statutory
requirement of the Stem Cell Therapeutic and Research Act of 2005
(Pub. L. 109-129). The Council is governed by the Federal Advisory
Committee Act (FACA), as amended (5 U.S.C. Appendix 2), which sets
forth standards for the formation and use of advisory committees.
DATES: Written nominations for membership on ACBSCT will be received
continuously.
ADDRESSES: Nomination packages must be submitted to the Executive
Secretary, ACBSCT, Healthcare Systems Bureau, HRSA, Room 08W60, 5600
Fishers Lane, Rockville, Maryland 20857, or sent via email to:
[email protected].
FOR FURTHER INFORMATION CONTACT: Shelley Grant, Executive Secretary,
ACBSCT, at (301) 443-8036 or email [email protected]. A copy of the
ACBSCT charter and a list of current members may be obtained by
accessing the ACBSCT website at https://bloodcell.transplant.hrsa.gov/about/advisory_council/.
SUPPLEMENTARY INFORMATION: ACBSCT was established pursuant to Public
Law 109-129 as amended by Public Law 111-264; 42 U.S.C. 274k; Section
379 of the Public Health Service Act. In accordance with Public Law 92-
463, the ACBSCT was chartered on December 19, 2006. ACBSCT meets up to
three times during the fiscal year.
ACBSCT shall, as requested by the Secretary, discuss and make
recommendations regarding the Program. It shall provide a consolidated,
comprehensive source of expert, unbiased analysis and recommendations
to the Secretary on the latest advances in the science of blood stem
cell transplantation. ACBSCT shall advise, assist, consult, and make
recommendations, at the request of the Secretary, on (1) broad Program
policy in areas such as the necessary size and composition of the adult
donor pool available through the Program and the composition of the
National Cord Blood Inventory, (2) requirements regarding informed
consent for cord blood donation, (3) accreditation requirements for
cord blood banks, (4) the scientific factors that define a cord blood
unit as high quality, (5) public and professional education to
encourage the ethical recruitment of genetically diverse donors and
ethical donation practices, (6) criteria for selecting the appropriate
blood stem source for transplantation, (7) program priorities; (8)
research priorities, and (9) the scope and design of the Stem Cell
Therapeutic Outcomes Database.
At the request of the Secretary, ACBSCT shall also review and
advise on issues relating more broadly to the field of blood stem cell
transplantation, such as regulatory policy pertaining to the
compatibility of international regulations, and actions that may be
taken by state and federal governments and public and private insurers
to increase donation and access to transplantation. ACBSCT shall also
make recommendations regarding research on emerging therapies using
cells from bone marrow and cord blood. The Council may meet up to three
times during the fiscal year.
Nominations: HRSA is requesting nominations for voting members to
serve as Special Government Employees (SGEs) on ACBSCT. The Council
shall consist of up to 25 members who are SGEs and 6 ex-officio, non-
voting members. The Secretary appoints ACBSCT SGEs with the expertise
needed to fulfill the duties of the Council. HRSA is seeking nominees
who are outstanding authorities and representatives of marrow donor
centers and marrow transplant centers; representatives of cord blood
banks and participating birthing hospitals; recipients of bone marrow
transplants; recipients of cord blood transplants; persons who require
such transplants; family members of such a recipient or
[[Page 28633]]
family members of a patient who has requested the assistance of the
Program in searching for an unrelated donor of bone marrow or cord
blood; persons with expertise in bone marrow and cord blood
transplantation; persons with expertise in typing, matching, and
transplant outcome data analysis; persons with expertise in the social
sciences; basic scientists with expertise in the biology of adult stem
cells; ethicists, hematology, and transfusion medicine researchers with
expertise in adult blood stem cells; persons with expertise in cord
blood processing; and members of the general public to serve as
members. Interested applicants may self-nominate or be nominated by
another individual or organization.
Individuals selected for appointment to ACBSCT will be invited to
serve for a term of 2 years, and are eligible to serve as many as 3
consecutive 2-year terms. Members appointed as SGEs receive a stipend
and reimbursement for per diem and travel expenses incurred for
attending ACBSCT meetings and/or conducting other business on behalf of
ACBSCT, as authorized by 5 U.S.C. 5703 of the FACA for persons employed
intermittently in government service.
The following information must be included in the package of
materials submitted for each individual being nominated for
consideration: (1) A letter of nomination stating the name,
affiliation, and contact information for the nominee, the basis for the
nomination (i.e., what specific attributes, perspectives, and/or skills
does the individual possess that would benefit the workings of ACBSCT),
and the nominee's field(s) of expertise; (2) a biographical sketch of
the nominee; (3) the name, address, daytime telephone number, and email
address at which the nominator can be contacted; and (4) a current copy
of the nominee's curriculum vitae. Nomination packages may be submitted
directly by the individual being nominated or by the person/
organization recommending the candidate.
HHS endeavors to ensure that the membership of ACBSCT is fairly
balanced in terms of points of view represented and that individuals
from a broad representation of geographic areas, gender, and ethnic and
minority groups, as well as individuals with disabilities, are
considered for membership. Appointments shall be made without
discrimination on the basis of age, ethnicity, gender, sexual
orientation, or cultural, religious, or socioeconomic status.
Individuals selected to be considered for appointment will be
required to provide detailed information regarding their financial
holdings, consultancies, and research grants or contracts. Disclosure
of this information is required for HRSA ethics officials to determine
whether there is a conflict between the SGE's public duties as a member
of ACBSCT and their private interests, including an appearance of a
loss of impartiality as defined by federal laws and regulations, and to
identify any required remedial action needed to address the potential
conflict.
Maria G. Button,
Director, Executive Secretariat.
[FR Doc. 2021-11213 Filed 5-26-21; 8:45 am]
BILLING CODE 4165-15-P
